<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8946">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790569</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000616663</org_study_id>
    <secondary_id>R01CA129226</secondary_id>
    <secondary_id>BUTLER-0807-004</secondary_id>
    <nct_id>NCT00790569</nct_id>
  </id_info>
  <brief_title>Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking</brief_title>
  <official_title>Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Butler Hospital</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is
      not yet known whether varenicline is more effective than the nicotine patch given together
      with nicotine gum in helping smokers quit smoking.

      PURPOSE: This randomized clinical trial is studying varenicline to see how well it works
      compared with the nicotine patch given together with nicotine gum in helping smokers in a
      methadone treatment program stop smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine whether varenicline, a nicotine receptor partial agonist, leads to a
           higher rate of smoking cessation than combination nicotine replacement therapy with
           nicotine patch prescription plus ad libitum nicotine gum delivery in
           methadone-maintained smokers.

      Secondary

        -  To test the effects of the treatments on smoking urges, withdrawal symptoms, and
           reinforcing effects of smoking.

        -  To test the effects of the treatments on methadone treatment outcomes, including
           retention in methadone maintenance, methadone dose changes, and continued use of
           illicit drugs as measured by urine toxicologies.

      OUTLINE: This is a multicenter study. Patients are stratified based on gender and level of
      nicotine dependence. Patients are randomized to 1 of 3 intervention arms.

      At baseline, all patients receive a minimal behavioral intervention using a 3-minute, simple
      smoking cessation counseling strategy, a self-help manual, and a telephone quit-line number.

        -  Arm I (varenicline): Patients receive oral varenicline once daily on days 1-3 and twice
           daily thereafter for a total of 6 months or when a comfortable level of smoking
           abstinence is reached.

        -  Arm II (placebo): Patients receive oral varenicline placebo once daily on days 1-3 and
           twice daily thereafter for a total of 6 months or when a comfortable level of smoking
           abstinence is reached.

        -  Arm III (nicotine patch/gum): Patients receive a nicotine patch, with doses tapering
           over time for a total of 26 weeks. Patients also receive nicotine gum to quell
           breakthrough urges. Patients may stop treatment when a comfortable level of smoking
           abstinence is reached.

      Patients complete a brief interview over 10-15 minutes at 2 weeks and monthly during months
      1-5. They complete a longer interview over 45 minutes at months 6 and 12 and provide breath
      samples (for carbon monoxide monitoring) and urine samples (for cotinine testing).

      NOTE: Smoking cessation may prevent certain smoking-related illnesses, including cancer.

      PROJECTED ACCRUAL: A total of 602 patients (258 receiving varenicline, 258 receiving
      nicotine replacement therapy, and 86 receiving placebo) will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>7-day Abstinence, Self-report</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rates of self-reported 7-day abstinence at 6-months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-day Abstinence, CO-confirmed</measure>
    <time_frame>6-Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rates of CO-confirmed 7-day abstinence at 6-months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of Smoking Cessation Continuous</measure>
    <time_frame>6-Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rates of self-reported continuous abstinence 6 Months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-day Abstinence, Self-reported</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rates of self-reported 7-day abstinence at 12-months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7-day Abstinence, CO-confirmed</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rates of CO-confirmed 7-day abstinence at 12-months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Smoking Urges</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal Symptoms</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention in Methadone Maintenance</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methadone Dose Changes</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Illicit Drugs as Measured by Urine Toxicologies</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinforcing Effects of Smoking</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Cigarettes Per Day</measure>
    <time_frame>6-Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in mean cigarettes per day</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Liver Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine</intervention_name>
    <description>Given transdermally and orally</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Current and regular cigarette smokers (over 10 cigarettes/day for the past 3 months)

          -  Interested in quitting smoking

               -  Willing to set a quit date 7 days after baseline assessment

          -  Participating in 1 of 5 methadone maintenance treatment programs across Rhode Island
             at any of the following institutions:

               -  Codac, Inc. (with two independent sites)

               -  Addiction Recovery Institute

               -  Center for Treatment and Recovery

               -  Discovery House

          -  Has received methadone for at least the past month

        PATIENT CHARACTERISTICS:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  English speaking

          -  Has a telephone or lives close to a relative or neighbor with a telephone

          -  Willing to make their methadone dose and methadone maintenance treatment program
             urine toxicologies available for review

          -  Available for this study for the next 12 months

          -  Not suffering from any unstable medical condition which would preclude the use of the
             nicotine patch (e.g., unstable angina or uncontrolled hypertension)

          -  No active skin condition (e.g., psoriasis)

          -  No history of skin allergy

          -  No history of a suicide attempt

          -  Not working as pilots, drivers, or operators of heavy machinery

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No concurrent insulin or blood thinners

          -  No concurrent smokeless tobacco, nicotine replacement therapy, or other smoking
             cessation treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Stein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Butler Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rhode Island Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>November 11, 2008</firstreceived_date>
  <firstreceived_results_date>December 12, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Butler Hospital</investigator_affiliation>
    <investigator_full_name>Michael Stein, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>adult primary liver cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>adult acute myeloid leukemia</keyword>
  <keyword>tobacco use disorder</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Arm II</title>
          <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
        </group>
        <group group_id="P3">
          <title>Arm III</title>
          <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>End of Treatment (6 Month Interview)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hospitalized</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Residential Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>End of Study (12 Month Interview)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible participants who completed enrollment and were randomized were included in baseline analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Arm III</title>
          <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="137"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="133"/>
                <measurement group_id="B4" value="315"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.2" spread="9.7"/>
                <measurement group_id="B2" value="40.6" spread="10.6"/>
                <measurement group_id="B3" value="40.3" spread="9.3"/>
                <measurement group_id="B4" value="39.9" spread="9.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="74"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="68"/>
                <measurement group_id="B4" value="159"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="63"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="65"/>
                <measurement group_id="B4" value="156"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="113"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="103"/>
                <measurement group_id="B4" value="250"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="38"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="120"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="116"/>
                <measurement group_id="B4" value="277"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="137"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="133"/>
                <measurement group_id="B4" value="315"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Years of Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11.8" spread="2.0"/>
                <measurement group_id="B2" value="11.4" spread="1.9"/>
                <measurement group_id="B3" value="11.9" spread="2.2"/>
                <measurement group_id="B4" value="11.8" spread="1.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Abstinence, Self-report</title>
        <description>Rates of self-reported 7-day abstinence at 6-months</description>
        <time_frame>6 Months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="133"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>7-day Abstinence, Self-report</title>
            <description>Rates of self-reported 7-day abstinence at 6-months</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Urges</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal Symptoms</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention in Methadone Maintenance</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Methadone Dose Changes</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Illicit Drugs as Measured by Urine Toxicologies</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reinforcing Effects of Smoking</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-day Abstinence, CO-confirmed</title>
        <description>Rates of CO-confirmed 7-day abstinence at 6-months</description>
        <time_frame>6-Months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="133"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>7-day Abstinence, CO-confirmed</title>
            <description>Rates of CO-confirmed 7-day abstinence at 6-months</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rates of Smoking Cessation Continuous</title>
        <description>Rates of self-reported continuous abstinence 6 Months</description>
        <time_frame>6-Months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="133"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Rates of Smoking Cessation Continuous</title>
            <description>Rates of self-reported continuous abstinence 6 Months</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Cigarettes Per Day</title>
        <description>Change in mean cigarettes per day</description>
        <time_frame>6-Months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="133"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Reduction in Cigarettes Per Day</title>
            <description>Change in mean cigarettes per day</description>
            <units>cigarettes/day</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.7" spread="9.2"/>
                  <measurement group_id="O2" value="-8.5" spread="9.2"/>
                  <measurement group_id="O3" value="-7.8" spread="9.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-day Abstinence, Self-reported</title>
        <description>Rates of self-reported 7-day abstinence at 12-months</description>
        <time_frame>12 Months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="133"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>7-day Abstinence, Self-reported</title>
            <description>Rates of self-reported 7-day abstinence at 12-months</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>7-day Abstinence, CO-confirmed</title>
        <description>Rates of CO-confirmed 7-day abstinence at 12-months</description>
        <time_frame>12 Months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="45"/>
                  <measurement group_id="O3" value="133"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>7-day Abstinence, CO-confirmed</title>
            <description>Rates of CO-confirmed 7-day abstinence at 12-months</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
varenicline: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
placebo: Given orally</description>
        </group>
        <group group_id="E3">
          <title>Arm III</title>
          <description>Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
nicotine: Given transdermally and orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Attack</sub_title>
                <description>Participant was hospitalized with symptoms of heat attack</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Participant Death</sub_title>
                <description>Participant died during study participation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Neurobehavioral Adverse Effects</sub_title>
                <description>Participant described hearing voices</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Neurobehavioral Adverse Events</sub_title>
                <description>Participant reported mood disturbance</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <description>Participants complained of skin rashes</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Stein</name_or_title>
      <organization>Butler Hospital</organization>
      <phone>401-455-6646</phone>
      <email>michael_stein@brown.ed</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
